Kevin Dennis Green Sells 55,225 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 55,225 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $2.06, for a total value of $113,763.50. Following the completion of the sale, the chief financial officer directly owned 1,195,891 shares of the company’s stock, valued at approximately $2,463,535.46. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The stock was sold at an average price of $2.01, for a total value of $55,869.96.

Cerus Price Performance

Shares of NASDAQ CERS opened at $1.79 on Thursday. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $343.98 million, a price-to-earnings ratio of -22.38 and a beta of 1.51. Cerus Corporation has a twelve month low of $1.12 and a twelve month high of $2.96. The business has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $1.86.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The firm had revenue of $64.58 million for the quarter, compared to analysts’ expectations of $59.31 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%. As a group, equities research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Investors Weigh In On Cerus

A number of hedge funds have recently added to or reduced their stakes in CERS. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Cerus by 321.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 46,801 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 35,692 shares during the period. Invesco Ltd. lifted its position in Cerus by 28.8% in the 4th quarter. Invesco Ltd. now owns 309,168 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 69,087 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in Cerus by 48.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 53,028 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 17,336 shares during the last quarter. Engineers Gate Manager LP boosted its stake in Cerus by 4.7% during the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 6,415 shares during the period. Finally, Kotler Kevin bought a new position in Cerus in the 4th quarter worth about $2,084,000. 78.37% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CERS. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. Wall Street Zen cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cerus currently has an average rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.